Home » Stocks » PTN

Palatin Technologies, Inc. (PTN)

Stock Price: $0.492 USD -0.005 (-0.91%)
Updated May 13, 2021 3:43 PM EDT - Market open
Market Cap 114.20M
Revenue (ttm) -452,531
Net Income (ttm) -26.61M
Shares Out 236.41M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $0.492
Previous Close $0.496
Change ($) -0.005
Change (%) -0.91%
Day's Open 0.500
Day's Range 0.480 - 0.517
Day's Volume 1,366,399
52-Week Range 0.375 - 1.300

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CRANBURY, N.J., May 4, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity...

1 week ago - PRNewsWire

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: APTX, BLRX, CYCN, LCTX
2 weeks ago - PennyStocks

CRANBURY, N.J., April 20, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...

3 weeks ago - PRNewsWire

CRANBURY, N.J., March 5, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...

2 months ago - PRNewsWire

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -100.00% and -182.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th...

2 months ago - Zacks Investment Research

CRANBURY, N.J., Feb. 17, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...

2 months ago - PRNewsWire

CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before ...

3 months ago - PRNewsWire

Palatin (PTN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

Palatin Technologies Inc (NYSE: PTN) filed an international patent application under the Patent Cooperation Treaty (PCT) related to the composition of PL9643 and a related family of melanocortin agonist...

3 months ago - Benzinga

CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...

3 months ago - PRNewsWire

Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.

3 months ago - Zacks Investment Research

Is (PTN) Outperforming Other Medical Stocks This Year?

3 months ago - Zacks Investment Research

CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...

4 months ago - PRNewsWire

Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2021 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

CRANBURY, N.J., Nov. 17, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulat...

5 months ago - PRNewsWire

CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the...

6 months ago - PRNewsWire

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

CRANBURY, N.J., Sept. 28, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modula...

7 months ago - PRNewsWire

CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 b...

7 months ago - PRNewsWire

CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

8 months ago - PRNewsWire

CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

8 months ago - PRNewsWire

CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

9 months ago - PRNewsWire

Shares of Palatin Technologies Inc. PTN, +2.50% gained 31.8% in premarket trading on Tuesday after it said it would test one of its investigational drugs as a treatment for COVID-19.

10 months ago - Market Watch

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q3 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2020 - Earnings Call Transcript

1 year ago - Seeking Alpha

Palatin Technologies' (PTN) CEO Carl Spana on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Every 10% of market share captured by Vyleesi is likely to generate $27 million in royalties for PTN.

1 year ago - Seeking Alpha

Palatin Technologies, Inc. (NYSEMKT:PTN) Q4 2019 Earnings Conference Call September 12, 2019 11:00 AM ET

1 year ago - Seeking Alpha

Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.

1 year ago - Zacks Investment Research

In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.

1 year ago - Zacks Investment Research

Is (PTN) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Palatin (PTN) closed the most recent trading day at $1, moving +0.37% from the previous trading session.

1 year ago - Zacks Investment Research

A high-profile analyst questioned the company's recent FDA approval.

1 year ago - The Motley Fool

Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc. treatment for hypoactive sex...

1 year ago - Market Watch

The demanded phase I trial showed consistent results compared to the previous trials and AMAGs CEO is: "fairly optimistic about the approval ability" of Vyleesi.

1 year ago - Seeking Alpha

Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.

Other stocks mentioned: ALXN, AMAG, MRK
1 year ago - The Motley Fool

Palatin Technologies' (PTN) CEO Carl Spana on Q3 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.

Other stocks mentioned: ANIP
2 years ago - Zacks Investment Research

About PTN

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic ... [Read more...]

Industry
Biotechnology
IPO Date
Oct 28, 1993
CEO
Carl Spana
Employees
20
Stock Exchange
NYSEAMERICAN
Ticker Symbol
PTN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PTN stock is "Strong Buy." The 12-month stock price forecast is 2.33, which is an increase of 373.67% from the latest price.

Price Target
$2.33
(373.67% upside)
Analyst Consensus: Strong Buy